Amber Stocco
Neurology · Bethany, OKNPI 1992930838
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,647 of the $4,427 with a category attached, or 82.4%. 34 manufacturers reported payments, led by Medtronic at 29.2% of the total. Reporting peaked in 2021 at $1,283 and has fallen 98.8% since, to $15 in 2025.
Across 178 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- UCB, Inc.$519
- Livanova USA, Inc.$471
- Eisai Inc.$414
- Supernus Pharmaceuticals, Inc.$326
- Greenwich Biosciences, Inc.$222
- plus $1K from 28 others
What the payments were for
- Travel & lodging$78018%
- Food & beverage$3,64782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 12 | $1,294 |
| UCB, Inc. | 34 | $519 |
| Livanova USA, Inc. | 16 | $471 |
| Eisai Inc. | 23 | $414 |
| Supernus Pharmaceuticals, Inc. | 24 | $326 |
| Greenwich Biosciences, Inc. | 8 | $222 |
| Jazz Pharmaceuticals Inc. | 5 | $134 |
| Amneal Pharmaceuticals LLC | 9 | $121 |
| Neurelis, Inc. | 6 | $115 |
| Novartis | 1 | $104 |
| Xeris Pharmaceuticals, Inc. | 4 | $90 |
| Immedica Pharma US, Inc. | 3 | $82 |
| Aquestive Therapeutics, Inc. | 4 | $69 |
| Tris Pharma Inc | 3 | $41 |
| PTC Therapeutics, Inc. | 2 | $41 |
| AstraZeneca | 2 | $41 |
| Biogen | 2 | $35 |
| Rhodes Pharmaceuticals L.p. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 2 | $31 |
| Biomarin Pharmaceutical Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Sanofi | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $16 |
| NS Pharma, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Abbott | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Percept$575
- PERCEPT PC BRAINSENSE$258
- ACTIVA$120
- AFINITOR$104
How this compares
$4,427 in reported general payments places this provider in the 60th percentile of 152 neurology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobazam | 12 | $2,883 |
| Lacosamide | 13 | $1,187 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bethany
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Jaclyn DuvallTulsa$1.4M
- Gregory ConnorTulsa$444K
- Brett DeesNorman$420K
- Eduardo de SousaMoore$393K
- Tania ReynaTulsa$353K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Baha Abu-EshehArdmore$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.